Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

DARMSTADT, Germany, June 11, 2018 /PRNewswire/ — Primary endpoints met in two clinical trials for investigational targeted therapy, tepotinib, as a monotherapy in MET-positive, advanced hepatocellular carcinoma (HCC) with Child-Pugh Class A liver function These data provide further evidence of tepotinib activity in patients with MET-positive advanced cancers Given

EMD Serono to Present MS Data and Debut New Patient Resources at CMSC 2018

EMD Serono to Present MS Data and Debut New Patient Resources at CMSC 2018

May 29, 2018 – Presentations for investigational Cladribine Tablets include analyses of NEDA and MRI outcomes in patients with relapsing MS – MS in the 21st Century to debut ‘My MS Priorities,’ a new tool to help improve patient-HCP dialogue

Merck data at ASCO 2018 to showcase progress and further optionality of oncology pipeline

May 17, 2018 Merck today announced new data from a number of high priority clinical development programs across its oncology portfolio to be presented at this year’s American Society of Clinical Oncology Annual Meeting. Two-year safety and efficacy data in

Merck to Use Genome Editing in Study of Gut Bacteria to Benefit Malnourished Children

16 MAY 2018 | DARMSTADT, GERMANY Merck today announced a collaboration with Washington University in St. Louis, Missouri, USA, that could lead to the optimizing of nutritional supplements to restore a healthy gut microbial community. • Collaboration with Washington University on gut

Official Ceremony: Merck Celebrates 350-Year Company History in Darmstadt

03 MAY 2018 | DARMSTADT, GERMANY Merck family representative Frank Stangenberg-Haverkamp: “Time and again, this company has reinvented itself. And we will continue to develop Merck further in the future as well.” Stefan Oschmann, Chairman of the Executive Board: “Merck has been

Mavenclad (Cladribine Tablets) Data in Multiple Sclerosis Journal Show an Even Greater Treatment Effect in Patients with Highly Active Multiple Sclerosis

02 MAY 2018 | DARMSTADT, GERMANY Post-hoc analysis from the 2-year CLARITY study demonstrated that Mavenclad reduced the risk of 6-month EDSS progression by 47% vs placebo Patients with highly active multiple sclerosis had an even greater treatment effect, reducing the risk

Merck to Develop Abituzumab in Metastatic Colorectal Cancer with SFJ Pharmaceuticals Group

02 MAY 2018 | DARMSTADT, GERMANY Agreement enables Merck to further develop abituzumab through a novel risk-sharing collaboration agreement SFJ Pharmaceuticals Group to develop abituzumab as a first-line treatment for metastatic colorectal cancer (mCRC) in combination with Erbitux® and chemotherapy Clinical program

350 Years of Merck: Company Looks Ahead to the Future

Merck held its 23rd Annual General Meeting today. The company’s 350th anniversary was one of the overriding themes. 27 APR 2018 | DARMSTADT, GERMANY 23rd Annual General Meeting in Frankfurt am Main A look back at business developments and strategic moves in